|Cel-Sci's Push Worth Watching|
|By Vinny Cassano|
|Saturday, 11 December 2010 00:00|
After dropping to a low of eighty one cents during trading last Tuesday, shares of Cel-Sci rebounded to above ninety once again on news that the company's manufacturing and laboratory operations were found to be compliant with European export regulations. This validation clears the way for the export of Multikine in support of the imminent Phase III trial that will measure the vaccine's effectiveness as a first line treatment for head and neck cancer.
The validation of the operations is another necessary step to be completed before launching the trial in full force, and as the company continues to chip away at the official legs of the process, investors are anxiously anticipating an actual launch date.
The sheer potential of Mulitikine as a first line treatment for head and neck cancer still makes CVM an attractive pick if Multikine is your bet because we'll have another Dendreon Provenge story on our hands if this product is successful in Phase III trials.
As always, the speculative biotech market contains no sure bets, so taking profits when the opportunities present themselves is a must in the sector.
Some have asked, "Why sell into a 'smaller' spike when the real money will be made when the good news plays out?"
Additionally, any long position remaining after the 'trading' shares are gone should more than suffice if a biotech rockets, but you don't want to refrain from taking some profits just because you're anticipating bigger gains - that's getting greedy.
The risk with Cel-Sci still exists, as we don't know how the Multikine trial will play out, but if the product works - then Cel-Sci will become, like Dendreon, a multi-billion dollar company.
Worth watching and worth the risk/reward accumulation, in my opinion.
Disclosure: Long CVM.
Vinny also authors the popular stock investing blog VFC's Stock House.